04th April 2022 | Pharma Updates
Ivermectin fails in a big trial; vaccination after COVID boosts immunity
People who recover from COVID-19 normally develop some immune responses against reinfection, but immunizations provide extra protection, particularly against severe disease.
SII's Covovax for people aged 12 and older earns a thumbs up from the panel
The government’s vaccine advisory body’s Covid-19 working group has suggested that Covovax from the Serum Institute of India be used in the nationwide vaccination campaign for people aged 12 and above.
MSD facing a delay in pneumococcal vaccine approval for the paediatric group
MSD had hoped to have additional indications for its pneumococcal vaccine Vaxneuvance for children and newborns by April, but the FDA recently pushed back the review date.
Probiotics are being used by researchers to treat Parkinson's disease
Probiotic bacteria that can generate the dopamine precursor L-DOPA, a potent cornerstone treatment for Parkinson’s disease, have been developed by researchers.
Bronchialthermoplasty discovered to be safe and long-lasting treatmentfor severe asthma
Patients with severe asthma experienced fewer exacerbations, ER visits, hospitalizations, and corticosteroid exposure five years after undergoing bronchial thermoplasty, as per recent study.
Zika and dengue fever could be the start of the next pandemic: WHO
Dengue fever infects 390 million people annually in 130 countries where it is endemic, as per WHO, while Zika virus created an outbreak in 2016 after it was discovered to cause birth problems such as microencephaly.
WHO has put a halt to the distribution of Covaxin through UN entities
World Health Organization said that the delivery of the coronavirus vaccination Covaxin through UN procurement agencies has been suspended.
As Russia registers Sputnik V version, world receives its first nasal covid jab
Russian Ministry of Health has approved the nasal version of Sputnik V, world’s first COVID-19 nasal vaccination and would be in general circulation and available for Russians within three to four months.
FDA approved Junshi Biosciences' INDA for advanced solid tumors
FDA has approved Shanghai Junshi Biosciences’ IND application for its anti-CD112R monoclonal antibody for the treatment of advanced solid tumors.
Prostate Cancer Biochemical Recurrence Imaging with 18F-Fluciclovine vs 68GaPSMA-11
Because presence of rising prostate specific antigen levels is usually a sign of recurrence, clinicians are eager for advancements in imaging that could aid in its detection.
